Interstitial lung diseases (ILDs) comprise a diverse group of pulmonary conditions characterized by inflammation and fibrosis of the lung parenchyma. These disorders, often progressive and challenging to manage, necessitate a comprehensive understanding for optimal patient care.
ILDs can be idiopathic or secondary to various factors such as occupational exposure, drug toxicity, or systemic diseases. The most common idiopathic form is idiopathic pulmonary fibrosis (IPF), while connective tissue diseases often underlie secondary ILDs. Precise classification is crucial for prognosis and treatment planning.
Patients typically present with exertional dyspnea and non-productive cough. Physical examination may reveal bibasilar crackles and finger clubbing. High-resolution computed tomography (HRCT) is the gold standard for diagnosis, often showing characteristic patterns such as reticular abnormalities and honeycombing. Pulmonary function tests reveal restrictive pattern with reduced diffusing capacity for carbon monoxide (DLCO).
Treatment is largely dependent on the underlying cause. For IPF, antifibrotic agents such as pirfenidone and nintedanib have shown to slow disease progression. In secondary ILDs, treating the underlying condition is paramount. Lung transplantation may be considered in selected patients. Multidisciplinary approach involving pulmonologists, radiologists, and pathologists is essential for comprehensive patient care.
Novel therapeutic approaches are being explored, including agents targeting molecular pathways involved in fibrosis, and the use of mesenchymal stem cells. Precision medicine, tailoring therapy based on genetic and molecular profiling, is an exciting frontier in ILD management.
Understanding ILDs requires a multifaceted approach encompassing accurate classification, thorough diagnostic evaluation, and appropriate treatment strategies. The advent of novel therapies and precision medicine holds promise for improved patient outcomes. As healthcare professionals, staying abreast of these advancements is crucial in managing these complex disorders.
1.
Research discovery halts childhood brain tumor before it forms
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
5.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
1.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
2.
AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance
3.
Preventing Sarcopenia During Cancer Treatment
4.
Guidance for Managing Complex Anticoagulation
5.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation